MigraineMind research summary

Persistence, effectiveness, and safety of CGRP-targeted therapies across therapeutic lines in resistant migraine: A real-world cohort study.

Headache | 2026

Observational study
AuthorsPons-Fuster E, Muñoz-García I, Mancebo-González A, Espuny-Miró A, González-Ponce CM
JournalHeadache
Publication year2026
PubMed ID43036971

Summary

Our research focused on how well patients with resistant migraines respond to CGRP-targeted therapies. We studied adults who received treatments like erenumab, fremanezumab, galcanezumab, atogepant, or rimegepant. These therapies aim to block a protein linked to migraine attacks. We looked at treatment persistence, effectiveness, safety, and patterns of treatment changes. Our study took place in a hospital over six years. We found that many patients switch between different CGRP-targeted therapies. This is important because understanding how these treatments work together can help doctors choose better options for patients. Our findings suggest that some factors can influence how well patients respond to these treatments. Overall, our work sheds light on real-world outcomes for people struggling with resistant migraines and highlights the need for more research in this area to improve patient care. Clinical relevance: This research highlights the importance of treatment sequencing in resistant migraine management, potentially guiding clinicians to optimize therapy choices for better patient outcomes.

Related migraine research topics

Original research

Read the original publication and review its full methods and findings on PubMed.

MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.